AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
2
JPMorgan CEO Jamie Dimon makes whirlwind visit to Israel
3
From IPO dreams to CrowdStrike’s crisis: Inside the collapse of the Wiz-Google mega deal
4
Israel’s Quantum Transistors receives €17.5M from the European Innovation Council for its quantum computing solution
5
Amdocs set to cut 1,500-3,000 jobs in new round of layoffs
More news

Allergan

8 stories about Allergan
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אלרגן משרדים

Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents

23.07.18|CTech
In September 2017, Allergan transferred six of its patents for blockbuster dry eye drug Restasis to the St. Regis Mohawk Tribe, hoping to protect the patents under the principle of sovereign immunity
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
default image

Allergan to Sell Teva Shares to J.P. Morgan

14.11.17|Dror Reich and Lilach Baumer
Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018
default image

Allergan Partners with Urine Incontinence Treatment Company

08.11.17|Lilach Baumer
Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
default image

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended